Clinical Trial

Study on Hibernation-like Therapy Based on Mechanical Thrombectomy

Study acronym: CHILL-1

Recruiting Phase 1

Record status

This record was last updated December 20, 2024 (before its estimated January 2025 completion). Its status may not reflect the trial's current state.

Summary

The goal of this clinical trial is to learn whether chlorpromazine and promethazine（C+P）is safe in Acute Ischemic Stroke（AIS) patients and determine the maximum dosage. It will also evaluate the preliminary efficacy of C+P in AIS. The main questions it aims to answer are: What is the optimal dosage of C+P that is safe without causing adverse effects in AIS patients? What is the optimal dosage of C+P that potentially works to treat AIS? Researchers will compare C+P with placebo (saline solution without C+P) to see if C+P is safe and effective in treating Acute Ischemic Stroke. Participants will: Receive C+P or placebo at the same time as endovascular thrombectomy begins. Patients will be observed for 72 hours to see if there were any adverse effects related to C+P. Infarct volumes will be evaluated using Computed Tomography. Functional outcomes will be assessed at 90 days.

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2024-10-27; most recent amendment 2024-12-18.

Status change: Not Yet Recruiting → Recruiting 2024-10-30

Trial Details

NCT Number	NCT06663631
Lead Sponsor	Capital Medical University Collaborators: Linyi People's Hospital
Conditions	Acute Ischemic Stroke
Enrollment	32 participants
Start Date	2024-11-09
Primary Completion	2025-01 (estimated)
Study Completion	2025-02 (estimated)
Updated on ClinicalTrials.gov	2024-12-20